Cipher Pharmaceuticals (TSE:CPH - Get Free Report) NASDAQ: CPHR received a C$12.50 price objective from analysts at Canaccord Genuity Group in a report issued on Monday, Marketbeat Ratings reports. The firm currently has a "hold" rating on the stock. Canaccord Genuity Group's target price would indicate a potential upside of 13.22% from the stock's previous close.
Cipher Pharmaceuticals Stock Performance
Shares of CPH traded down C$0.05 on Monday, reaching C$11.04. 17,173 shares of the stock traded hands, compared to its average volume of 36,537. The firm has a market cap of C$198.20 million, a price-to-earnings ratio of 12.19 and a beta of 1.20. Cipher Pharmaceuticals has a 12 month low of C$8.01 and a 12 month high of C$19.69. The stock's 50-day moving average price is C$12.31 and its 200-day moving average price is C$13.98. The company has a debt-to-equity ratio of 41.22, a current ratio of 2.00 and a quick ratio of 2.67.
Insider Activity at Cipher Pharmaceuticals
In other news, Director Harold Morton Wolkin sold 3,500 shares of the company's stock in a transaction dated Monday, March 24th. The shares were sold at an average price of C$13.49, for a total value of C$47,215.00. 42.00% of the stock is currently owned by insiders.
Cipher Pharmaceuticals Company Profile
(
Get Free Report)
Cipher Pharmaceuticals Inc is a specialty pharmaceutical company. Its products include Dermatology Products, Hospital Acute Care Products, and Out-Licensed Products among others. The company's geographical segments include Canada and the United States.
Read More
Before you consider Cipher Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cipher Pharmaceuticals wasn't on the list.
While Cipher Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
